Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | STAT6 | P42226 | 2/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 2/20 | 0.30 |
| ▸ | CTSK | P43235 | 2/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22069860 | 1.00 | TUBB1 (0.49) | TUBB1SMN1; SMN2STAT6MMP13CTSS | |
| SCHEMBL58263 | 1.00 | TUBB1 (0.49) | TUBB1SMN1; SMN2STAT6MMP13CTSS | |
| SCHEMBL13660105 | 1.00 | TUBB1 (0.49) | TUBB1SMN1; SMN2STAT6MMP13CTSS | |
| SCHEMBL13681918 | 0.94 | TUBB1 (0.49) | TUBB1SMN1; SMN2STAT6 | |
| SCHEMBL6675848 | 0.94 | TUBB1 (0.44) | TUBB1SMN1; SMN2MMP13 | |
| SCHEMBL6675844 | 0.94 | TUBB1 (0.44) | TUBB1SMN1; SMN2MMP13 | |
| SCHEMBL29511164 | 0.93 | TUBB1 (0.49) | TUBB1 | |
| SCHEMBL6807317 | 0.92 | TUBB1 (0.56) | TUBB1MMP13 | |
| SCHEMBL29511292 | 0.91 | TUBB1 (0.47) | TUBB1 | |
| SCHEMBL6803333 | 0.91 | TUBB1 (0.59) | TUBB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633224-B2 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | EISAI CO., LTD. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-8633224-B2 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | EISAI CO., LTD. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | TUBB1 1330/4885SMN1; SMN2 4520/4885STAT6 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.